Home \ Antibodies \ C3aR, Mouse, mAb 14D4
Catalog # HM1123

C3aR, Mouse, mAb 14D4

The monoclonal antibody 14D4 reacts with mouse C3aR, which is a member of the rhodopsin superfamily of 7-transmembrane G protein-coupled receptors, with a molecular weight of approximately 54 kDa.

Read more
Please choose the quantity of items you wish to add to your cart…
Find distributor

The monoclonal antibody 14D4 reacts with mouse C3aR, which is a member of the rhodopsin superfamily of 7-transmembrane G protein-coupled receptors, with a molecular weight of approximately 54 kDa.

Expression of C3aR has been demonstrated on a wide variety of immune cells, including monocytes, macrophages, dendritic cells, neutrophils, basophils, eosinophils, mast cells, T lymphocytes and B lymphocytes. In addition, C3aR is found on cells of the central nervous system, lungs and kidney. In the course of complement activation C3aR functions as the cell surface receptor for C3a, which is the C-terminal 77 amino acid cleavage product of C3. C3a, possesses both anaphylatoxic and immunoregulatory properties, such as smooth muscle contraction, histamine release from mast cells, and enhanced vascular permeability.

In addition, C3a induces respiratory burst in neutrophils and has chemotactic properties for eosinophils and mast cells. Moreover, C3a causes release of key cytokines from multiple cell types, including IL-1β, TNF-α, IL-6 and IL-8. A role for C3aR has been implicated in several murine disease models. It was shown that C3aR inhibition reduces neurodegeneration in experimental lupus, whereas in a murine model of allergic airway disease, deletion of the C3a receptor protects against the changes in lung physiology seen after allergen challenge. Finally, it was shown that deletion of C3aR is protective in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis.

Flow cytometry, Frozen sections

Application Notes
FC: Antibody 14D4 stains the extracellular domain of C3aR when RBL-2H3 transfectants and human monocytes are used. Primary antibody concentrations were 5µg/ml. (Ref.1) IHC-F: Tissue sections were fixed in acetone. To block unspecific binding of Abs, sections were incubated with PBS and heat aggregated human IgG at 300 µg/ml (Ref.1).

For immunohistochemistry and flow cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

Product type
Monoclonal antibodies
100 µg, 20 µg
0.2 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide.
RBL-2H3 transfectants expressing mouse C3aR
Rat IgG2a
Storage and stability
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Infectious diseases, Nephrology
CoA-TDS HM1067-HM2099 Safety Data Sheet

You may be interested in…

Calculate your ELISA data easily

With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.

Latest Hycult Biotech news

  • New Human Complement Pathway Assays
    We are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
  • Navigating the pitfalls in complement analysis
    Our colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
  • NEW Human C3d ELISA
    We are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA
Contact us